Target Pipelines

Subscribe to
our newsletters!

Showing 41–60 of 62 results

  • August of 2020
    This report describes the landscape of industry-driven approaches to discover and develop recombinant therapeutic antibodies against SARS-CoV-2 for treatment of COVID-19
     200.00
  • April of 2020
    This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.
     150.00
  • March of 2020
    Report about SARS-CoV-2 Treatment & Prevention Approaches undertaken by industry to evaluate existing and discover novel treatments and vaccines for COVID-19.
     150.00
  • February of 2020
    This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.
     100.00
  • October of 2019
    This report about KRAS Inhibitors evaluates the landscape of investigational small molecules, antibodies, cell therapeutics and vaccines targeting KRAS for treatment of cancer
     250.00
  • September of 2019
    This report evaluates the landscape of small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.
     250.00
  • July of 2019
    This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.
     150.00
  • July of 2019
    This Target Pipeline List provides an overview of FGF21 receptor agonists in development for treatment of obesity, diabetes and non-alcoholic steatohepatitis (NASH).
     50.00
  • June of 2019
    This Target Pipeline List provides an overview of P2X3 receptor antagonists in development for treatment of chronic cough, endometriosis and neuropathic pain.
     50.00
  • June of 2019
    This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.
     50.00
  • May of 2019
    This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)
     150.00
  • April of 2019
    This report provides an overview of small molecule inhibitors of Tyk2 in development for treatment of inflammatory diseases.
     125.00
  • April of 2019
    This report provides an overview of small molecule inhibitors of NLRP3 in development for treatment of chronic inflammatory diseases.
     75.00
  • April of 2019
    This report provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.
     50.00
  • April of 2019
    This report provides an overview of therapeutic proteins in development for treatment of arginine-dependent tumors or for enzyme replacement therapy.
     75.00
  • March of 2019
    This Target Pipeline List provides an overview of biologic and chemical entities on the market or in development for treatment of hyperuricemia associated with gout or tumor lysis
     150.00
  • February of 2019
    This report provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.
     100.00
  • January of 2019
    This Target Pipeline List provides an overview of biologic and small molecule approaches to raise high density lipoprotein (HDL) for reduction of recurrent cardiovascular events.
     100.00
  • December of 2018
    This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.
     75.00
  • January of 2019
    This Target Pipeline List provides an overview of agonist antibodies and fusion proteins targeting death receptor 4 and/or 5 in development for treatment of cancer.
     100.00